tovetumab
mAbexperimental
Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer. It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer. Development was discontinued in 2013. — Wikipedia
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT00816400)
Timeline
Indications
Mechanism of action
PDGFRA inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTovetumab ↗
- ChEMBLCHEMBL2364651 ↗
Also known as
- medi-575
- medi-575
- tovetumab
- tovetumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01268566 | Phase 2 | Jan 1, 2011 | MedImmune |
| NCT01268059 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2010 | MedImmune |
| NCT01102400 | Phase 1 | Mar 1, 2010 | AstraZeneca, MedImmune |
| NCT00816400 | Phase 1 | Mar 1, 2009 | MedImmune |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 4 | 3 | 2 | 2009 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2010 |
2 organizations
Page 1 / 1